PLX - Protalix BioTherapeutics, Inc. Stock Analysis & Valuation

Protalix BioTherapeutics, Inc. (PLX) trades at $2.59 with an EquitAI Valuation DNA score of 2/10 and Quality score of 9/10. The company's trailing P/E ratio is 10.7x. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Wall Street analysts have a consensus 12-month price target of $6.0 for Protalix BioTherapeutics, Inc. (PLX), representing an implied 131.7% upside from its current trading level of $2.59 with an average rating of Buy based on 1 analyst rating. Because this forecast is provided by a single analyst, it represents limited coverage and may reflect historical or isolated expectations rather than a broad consensus. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Protalix BioTherapeutics, Inc. does not currently pay a regular dividend yield, prioritizing capital reinvestment into operations, product development, and balance sheet strength.

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.